Control APC Raji Cells

Human lymphoblast cells  - Bio-IC™ control cells

ABOUT

Activating control APC for anti-immune checkpoint cell-based assay

InvivoGen has developed Raji-APC-Null cells, as antigen-presenting cells (APCs), from the human B lymphoblastic Raji cell line.

• Raji-APC-Null cells – Antigen-Presenting Cells for Jurkat-Lucia™ TCR-derived cells

These cells differ from Raji-Null cells.
In addition to the high endogenous surface expression of CD80/86 activatory molecules, Raji-APC-Null cells feature the stable cell surface expression of a specific antigenic peptide complexed with HLA molecules ([HLA::peptide]). Thus, Raji-APC-Null, but not Raji-Null cells, can be used as activating APCs for Jurkat-Lucia™ TCR-derived cells.
A first signal (signal 1) is delivered upon recognition of [HLA::peptide] on Raji-APC cells by the TCR on Jurkat-Lucia™ cells. A second signal (signal 2), also known as the co-stimulation signal, is operated by the interaction of CD80/86 and CD28 molecules at the surface of the APC and Jurkat-Lucia™ TCR cells, respectively. Raji-APC-Null cells express immune checkpoints (ICs) at very low to barely detectable levels, so they serve as control APC for InvivoGen's anti-immune checkpoint cell-based assay (Bio-IC™).

 

More details More details

 

Key features:

  • Stable specific [HLA::peptide] expression
  • Endogenous hCD80/86 expression
  • Very low (barely detectable) expression levels to no expression of immune checkpoints (ICs)

Application:

Raji-APC-Null cells have been designed as control APCs for InvivoGen’s PD-1/PD-L1 Bio-IC™.
These cells do not provide an immune checkpoint signal to the Jurkat-Lucia™ TCR-hPD-1 effector reporter cells.

 

Read our review Read our review on Immune Checkpoint Blockade

Learn more about Immune Checkpoint Antibodies Learn more about Immune Checkpoint Antibodies

Disclaimer:  These cells are for internal research use only and are covered by a Limited Use License (See Terms and Conditions). Additional rights may be available.

SPECIFICATIONS

Specifications

Species
Human
Tested applications

Control APCs for PD-1/PD-L1 Bio-IC™

Cell type
Lymphoblastic
Growth properties
Suspension
Tissue origin
Human B cell lymphoma
Antibiotic resistance
Blasticidin
G418 (mammalian cells)
Growth medium

Complete IMDM (see TDS)

Mycoplasma-free

Verified using Plasmotest™

Quality control

Each lot is functionally tested and validated.

CONTENTS

Contents

  • Product: 
    Raji-APC-Null Cells
  • Cat code: 
    raji-apc-null
  • Quantity: 
    3-7 x 10^6 cells
Includes:
  • 1 ml of Blasticidin (10 mg/ml)
  • 1 ml of G418 (Geneticin) (100 mg/ml)
  • 1 ml of Normocin™ (50 mg/ml). Normocin™ is a formulation of three antibiotics active against mycoplasmas, bacteria, and fungi.

Shipping & Storage

  • Shipping method:  Dry ice
  • Storage:

    • Liquid nitrogen vapor
    Stability: 20 passages

Details

The activation of T lymphocytes initiates their proliferation and yields a variety of effector functions that allow combating microbial infections, as well as developing tumors. The current paradigm is that full activation of T cells requires at least 2 signals upon contact with antigen-presenting cells (APCs) [1, 2].

Signal 1 is delivered through the interaction of the T cell receptor (TCR) and a specific antigenic peptide associated with an MHC (major histocompatibility complex) molecule on APCs. Signal 2 is delivered through the interaction of CD28, the prototypical T cell co-stimulatory molecule, and its ligands, CD80 or CD86, expressed by the APC. However, a number of other molecules, named immune checkpoints (IC), have been reported to regulate the onset and the limitations of T cell activities. PD-1 (programmed cell death 1) receptor and its ligand, PD-L1, are among the best characterized suppressive immune checkpoints [3].

 

Signal 1: TCR and [HLA::peptide]

The 'classical' and most represented TCR is an 80 to 90 kDa heterodimer composed of one α chain and one β chain. The αβTCR is a transmembrane protein expressed by developing and mature T cells. It features an extracellular ligand-binding pocket and a short cytoplasmic tail. Each αβTCR is restricted to a specific complex made of an antigenic peptide and a class I or class II MHC molecule. Human MHC molecules are also known as HLA (human leukocyte antigen). Because of its short cytoplasmic tail, the TCR, once engaged,  lacks the ability to signal and requires non-covalent association with the CD3 to trigger downstream intracellular signaling and T cell activation [1, 2]. Importantly, signal 1 without co-stimulation results in T cell unresponsiveness or 'anergy', a tolerance mechanism that guards against premature activation.

 

Signal 2: CD28 and CD80/86

CD28 is a homodimeric and transmembrane protein expressed by T cells. Nearly all human CD4+ T cells and 50% of human CD8+ T cells express CD28. The CD28 interaction with CD80 (aka B7-1) or CD86 (aka B7-2) on APCs, in conjunction with TCR engagement, triggers a co-stimulation signal (signal 2). It results in T cell proliferation, cytokine production, cell survival, and cellular metabolism [1, 2].

 

IC signal: PD-1 and PD-L1

— PD-1 (programmed cell death 1; also known as CD279) is a type I transmembrane protein expressed at the cell surface of activated and exhausted conventional T cells. PD-1 is an inhibitory immune checkpoint that prevents T-cell overstimulation and host damage. PD-1 interaction with its ligands PD-L1 and PD-L2 induces inhibition of TCR signaling [3].

— PD-L1 (programmed cell death ligand 1; also known as CD274 or B7-H1) is a transmembrane protein expressed at the cell surface of hematopoietic and nonhematopoietic cells and is induced by pro-inflammatory cytokines, such as in the tumor microenvironment  [3].  PD-L1 is one ligand for PD-1, an inhibitory immune checkpoint receptor that is expressed by activated and exhausted T cells. PD-1:PD-L1 interaction induces inhibition of TCR signaling, thereby preventing T-cell overstimulation and host damage [3].

 

References:

1. Budd R.C. & Fortner K.A., 2017. Chapter 12 - T Lymphocytes. Kelley and Firestein's Textbook of Rheumatology (Tenth Edition). pages 189-206.
2. Smith-Garvin J.E. et al., 2009. T Cell Activation. Ann. Rev. Immunol. 27:591-619.
3. Ribas A. and Wolchock J.D., 2018. Cancer immunotherapy using checkpoint blockade. Science. 359:1350-55.

DOCUMENTS

Documents

Raji-APC-Null Cells

Technical Data Sheet

Validation Data Sheet

Safety Data Sheet

Certificate of analysis

Need a CoA ?

CUSTOMER SERVICE & TECHNICAL SUPPORT

Question about this product ?